Journal article
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.
Abstract
BACKGROUND: The cardiovascular risk associated with early renal insufficiency is unknown. Clinicians are often reluctant to use angiotensin-converting enzyme inhibitors in patients with renal insufficiency.
OBJECTIVE: To determine whether mild renal insufficiency increases cardiovascular risk and whether ramipril decreases that risk.
Authors
Mann JFE; Gerstein HC; Pogue J; Bosch J; Yusuf S
Journal
Annals of Internal Medicine, Vol. 134, No. 8, pp. 629–636
Publisher
American College of Physicians
Publication Date
April 17, 2001
DOI
10.7326/0003-4819-134-8-200104170-00007
ISSN
1056-8751